Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amorfix Life Sciences, a theranostics company, and BioMosaics, a cancer biomarker development company, have formed a collaboration to develop and commercialize a blood-based assay for early detection of hepatocellular carcinoma or primary liver cancer.
Subscribe to our email newsletter
This effort is possible due to an ‘Intellectual Property Development and Commercialization Program’ investment of $280,000 from the Ontario Institute for Cancer Research to Sunnybrook Research Institute (SRI) at Sunnybrook Health Sciences Centre.
The collaboration incorporates existing technology for the blood test licensed to BioMosaics, plus new material from SRI needed to improve the test, to be used for assay development at Amorfix. Pending successful development, the product will be commercialized by BioMosaics through its existing distribution network.
Under this commercial collaboration, BioMosaics will have the opportunity to market the new test directly, as well as through its existing distributors, and Amorfix will receive royalties on commercial product sales, as well as an option to manufacture the assay kits and reagents for global distribution. The collaboration utilizes BioMosaics’s expertise in the cancer biomarker area and the assay development capability at Amorfix.
George Adams, CEO of Amorfix, said: “Our expertise in developing highly sensitive blood assays is part of our core capabilities and we welcome the opportunity to apply our knowledge to achieve a blood test for the early detection of primary liver cancer.”